非一线核苷(酸)类似物经治慢性乙型肝炎患者治疗策略调整专家共识

2019-06-15 中华医学会肝病学分会 中国实用内科杂志.2019.36(5):529-532.

口服核苷( 酸) 类似物(NAs) 抗病毒治疗是治疗慢性乙型肝炎(CHB) 重要和有效的方法之一。从抗病毒作用强弱及耐药方面考虑,国内外指南将NAs 类药物分为一线和非一线用药。《非一线核苷( 酸) 类似物经治慢性乙型肝炎患者治疗策略调整专家共识》主要针对目前正在使用非一线NAs 类药物且有效的患者,如何规范地调整为一线NAs 类药物,并强化CHB 初始抗病毒治疗必须选择一线NAs 类药物,使患者

中文标题:

非一线核苷(酸)类似物经治慢性乙型肝炎患者治疗策略调整专家共识

发布日期:

2019-06-15

简要介绍:

口服核苷( 酸) 类似物(NAs) 抗病毒治疗是治疗慢性乙型肝炎(CHB) 重要和有效的方法之一。从抗病毒作用强弱及耐药方面考虑,国内外指南将NAs 类药物分为一线和非一线用药。《非一线核苷( 酸) 类似物经治慢性乙型肝炎患者治疗策略调整专家共识》主要针对目前正在使用非一线NAs 类药物且有效的患者,如何规范地调整为一线NAs 类药物,并强化CHB 初始抗病毒治疗必须选择一线NAs 类药物,使患者既可以获得更好的抗病毒疗效,提高患者的依从性,同时又可避免药物严重不良反应的发生。 

拓展指南:乙型肝炎相关指南:

下载附件:

(因为版权问题,不支持下载)

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=896891, encodeId=213a896891ec, content=学习学习,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9982355661, createdName=122be478m99暂无昵称, createdTime=Wed Nov 04 16:35:33 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886254, encodeId=c79e88625494, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66655418741, createdName=哈哈哈哈哈hlx, createdTime=Fri Sep 18 07:11:34 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368242, encodeId=25bf36824288, content=666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Mon Jun 24 06:13:22 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2020-11-04 122be478m99暂无昵称

    学习学习,谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=896891, encodeId=213a896891ec, content=学习学习,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9982355661, createdName=122be478m99暂无昵称, createdTime=Wed Nov 04 16:35:33 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886254, encodeId=c79e88625494, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66655418741, createdName=哈哈哈哈哈hlx, createdTime=Fri Sep 18 07:11:34 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368242, encodeId=25bf36824288, content=666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Mon Jun 24 06:13:22 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2020-09-18 哈哈哈哈哈hlx

    很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=896891, encodeId=213a896891ec, content=学习学习,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9982355661, createdName=122be478m99暂无昵称, createdTime=Wed Nov 04 16:35:33 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886254, encodeId=c79e88625494, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66655418741, createdName=哈哈哈哈哈hlx, createdTime=Fri Sep 18 07:11:34 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368242, encodeId=25bf36824288, content=666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Mon Jun 24 06:13:22 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2019-06-24 百草

    666

    0